In the last trading session, 1.82 million Rani Therapeutics Holdings Inc (NASDAQ:RANI) shares changed hands as the company’s beta touched 0.14. With the company’s per share price at $2.68 changed hands at $0.05 or 1.90% during last session, the market valuation stood at $78.50M. RANI’s last price was a discount, traded about -226.49% off its 52-week high of $8.75. The share price had its 52-week low at $1.82, which suggests the last value was 32.09% up since then. When we look at Rani Therapeutics Holdings Inc’s average trading volume, we note the 10-day average is 8.85 million shares, with the 3-month average coming to 1.38 million.
Analysts gave the Rani Therapeutics Holdings Inc (RANI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RANI as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Rani Therapeutics Holdings Inc’s EPS for the current quarter is expected to be -0.26.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Rani Therapeutics Holdings Inc (NASDAQ:RANI) trade information
Instantly RANI was in green as seen at the end of in last trading. With action 32.67%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -19.28%, with the 5-day performance at 32.67% in the green. However, in the 30-day time frame, Rani Therapeutics Holdings Inc (NASDAQ:RANI) is 16.02% up. Looking at the short shares, we see there were 0.79 million shares sold at short interest cover period of 10.51 days.
The consensus price target for the stock as assigned by Wall Street analysts is 10, meaning bulls need an upside of 73.2% from its current market value. According to analyst projections, RANI’s forecast low is 9 with 28 as the target high. To hit the forecast high, the stock’s price needs a -944.78% plunge from its current level, while the stock would need to soar -235.82% for it to hit the projected low.
Rani Therapeutics Holdings Inc (RANI) estimates and forecasts
Data shows that the Rani Therapeutics Holdings Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -62.09% over the past 6 months, a 26.32% in annual growth rate that is considerably higher than the industry average of 17.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0.28%. The 2024 estimates are for Rani Therapeutics Holdings Inc earnings to increase by 7.44%, but the outlook for the next 5-year period is at -9.40% per year.
RANI Dividends
Rani Therapeutics Holdings Inc is expected to release its next quarterly earnings report in November.
Rani Therapeutics Holdings Inc (NASDAQ:RANI)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 30.61% of Rani Therapeutics Holdings Inc shares while 9.99% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 14.40%. There are 9.99% institutions holding the Rani Therapeutics Holdings Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 2.7265% of the shares, roughly 0.71 million RANI shares worth $2.7 million.
NAN FUNG GROUP HOLDINGS LTD holds the second largest percentage of outstanding shares, with 1.8959% or 0.49 million shares worth $1.88 million as of 2024-06-30.
